These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 34054309)

  • 1. Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib.
    Fiala O; Ostašov P; Rozsypalová A; Hora M; Šorejs O; Šustr J; Bendová B; Trávníček I; Filipovský J; Fínek J; Büchler T
    Cancer Manag Res; 2021; 13():4077-4086. PubMed ID: 34054309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line.
    Fiala O; Ostašov P; Rozsypalová A; Hora M; Šorejs O; Šustr J; Bendová B; Trávníček I; Filipovský J; Fínek J; Büchler T
    Target Oncol; 2021 Sep; 16(5):643-652. PubMed ID: 34363554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting.
    Nikic P; Babovic N; Dzamic Z; Salma S; Stojanovic V; Matkovic S; Pejcic Z; Juskic K; Soldatovic I
    Front Oncol; 2022; 12():892156. PubMed ID: 35756652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 5. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.
    Deng H; Huang Y; Hong Z; Yuan X; Cao Z; Wei Y; Zhang W
    BMC Cancer; 2019 May; 19(1):489. PubMed ID: 31122210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?
    Bonadioa RC; Velho PI; Marta GN; Nardo M; Souza MC; Muniz DQ; Bezerra RO; Bispo RK; Faraj SF; Bastos DA; Dzik C
    Ecancermedicalscience; 2019; 13():973. PubMed ID: 31921344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
    Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
    J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.
    Keizman D; Ish-Shalom M; Sella A; Gottfried M; Maimon N; Peer A; Hammers H; Eisenberger MA; Sinibaldi V; Neiman V; Rosenbaum E; Sarid D; Mermershtain W; Rouvinov K; Berger R; Carducci MA
    Clin Genitourin Cancer; 2016 Oct; 14(5):420-425. PubMed ID: 27211307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer.
    Köstek O; Yılmaz E; Hacıoğlu MB; Demircan NC; Gökyer A; Uzunoğlu S; Tunçbilek N; Çiçin İ; Erdoğan B
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):735-742. PubMed ID: 30680522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
    Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
    Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
    BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
    Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
    Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.
    Lalani AA; Li H; Heng DYC; Wood L; Kalirai A; Bjarnason GA; Sim HW; Kollmannsberger CK; Kapoor A; Hotte SJ; Vanhuyse M; Czaykowski P; Reaume MN; Soulieres D; Venner P; North S; Basappa NS
    Can Urol Assoc J; 2017; 11(3-4):112-117. PubMed ID: 28515811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience.
    Pierantoni F; Basso U; Maruzzo M; Lamberti E; Bimbatti D; Tierno G; Bergo E; Brunello A; Zagonel V
    J Geriatr Oncol; 2021 Mar; 12(2):290-297. PubMed ID: 32972885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
    Sorich MJ; Kichenadasse G; Rowland A; Woodman RJ; Mangoni AA
    Int J Cancer; 2016 May; 138(9):2293-9. PubMed ID: 26685869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.
    Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason G; Heng D; Soulières D; Reaume N; Basappa N; Lévesque E; Dragomir A
    Curr Oncol; 2018 Dec; 25(6):e576-e584. PubMed ID: 30607126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study.
    Chen J; Ye W; Jiang W; Li X; Liu R; Lin B; Xiang J; Tian W; Bai J; Zuo T; Lin B; Guo Y; Zheng S
    Transl Androl Urol; 2021 Mar; 10(3):1321-1331. PubMed ID: 33850766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
    McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
    Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies.
    Sheng X; Jin J; He Z; Huang Y; Zhou A; Wang J; Ren X; Ye D; Zhang X; Qin S; Zhou F; Wang B; Guo J
    BMC Cancer; 2020 Mar; 20(1):219. PubMed ID: 32171288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.